Fubin Li

Title: Fubin Li: Innovator in Antibody Engineering

Introduction

Fubin Li is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of antibody engineering, particularly in enhancing the efficacy of therapeutic antibodies. His innovative work focuses on improving the agonistic activity of antibodies, which is crucial for treating various diseases.

Latest Patents

Fubin Li holds a patent titled "Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity." This patent describes a heavy chain constant region that includes a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain. The sequences of the CH1 domain and hinge region are derived from human IgG2, while the CH2 and CH3 domains are based on human IgGs. This unique configuration allows the antibody heavy chain constant region to have an affinity to human FcγRIIB that is equal to or higher than that of human IgG1. The invention significantly enhances the agonistic activity of antibodies or fusion proteins, improving their efficacy in treating tumors and autoimmune diseases.

Career Highlights

Fubin Li is affiliated with Shanghai Jiao Tong University, where he conducts research and develops innovative solutions in the field of biotechnology. His work has garnered attention for its potential impact on therapeutic applications and disease treatment.

Collaborations

Fubin Li collaborates with notable colleagues, including Yan Zhang and Huan Shi. Their combined expertise contributes to advancing research in antibody engineering and related fields.

Conclusion

Fubin Li's contributions to antibody engineering exemplify the importance of innovation in medical science. His patented work enhances the therapeutic potential of antibodies, paving the way for improved treatments for serious health conditions.